Advances in the Knowledge and Treatment of Autoimmunity joint with Immunopathology of Type 1 Diabetes Organizer(s): Juan Rivera, Virginia Pascual and David M. Lee Date: April 04 - 09, 2013
Location: Fairmont Chateau Whistler, Whistler, BC, CanadaUnderstanding the mechanisms by which tolerance is induced and circumvented is important for the development of new therapies for autoimmune disorders. While significant progress has been made in understanding the basic processes of both central and peripheral tolerance, the integration of these mechanisms in the context of the pathogenesis of autoimmunity is still in its infancy. In the past few years, considerable effort has been made in bringing together the fundamental mechanisms, the genetics and genomics, the cellular players, and the clinical features of disease towards developing novel therapeutic strategies. These efforts have also advanced our understanding of the pathogenesis of autoimmunity and revealed new players and potential therapeutic strategies in treatment of autoimmunity. The goal of this Keystone Symposia meeting on Advances in the Knowledge and Treatment of Autoimmunity is to bring together scientists and clinicians to discuss what we are learning from the information obtained from mouse models, patient studies and the use of novel targeted therapies. Both common and unique immune-mediated mechanisms leading to autoimmune diseases will be highlighted. The meeting will cover advances in genomic and cellular approaches, biomarker discovery, and in targeted therapies. The accompanying workshops will be designed to promote interactions and collaborations between academic and R & D scientists to respond to the challenges in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Immunopathology of Type 1 Diabetes, which will share a keynote session and two plenary sessions with this meeting. Scholarship Deadline: December 4 2012 Discounted Abstract Deadline: December 4 2012 Abstract Deadline: January 4 2013 Discounted Registration Deadline: February 4 2013 We gratefully acknowledge additional support for this conference from:  We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
ImmusanT, Inc.
Novartis Institutes for BioMedical Research
We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID)Grant No. 1R13AI106184-01 The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. |